Browse articles from EyeWorld.org related to MIGS. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Researchers develop living 3D lab model of human retina ➤ Real-world data shows home AMD monitoring program is better than standard of care ➤ FDA approves new ophthalmic viscosurgical device ➤ Positive topline data for photobiomodulation for dry AMD ➤ Positive topline data for bevacizumab-vikg for retinal indications
➤ FDA approves elements of artificial vision system for blind patients ➤ Expanded indication for MIGS device ➤ 5-year pivotal trial data for MIGS device ➤ Topline results from Phase 2 study of investigational MGD treatment
➤ FDA accepts NDA for fixed-combination mydriatic agent ➤ NDA accepted by FDA for dry eye nasal spray ➤ NDA submitted for drop to treat presbyopia ➤ Study to assess outcomes of ab interno canaloplasty ➤ Largest study of glaucoma genetics published ➤ Iridex and Topcon enter into strategic agreement ➤ COVID-19 vaccine update ➤ ASCRS Journal Club on March 11
➤ Commercial launch of Alcon’s Vivity IOL ➤ Topline results from Phase 2 trial for treatment of contact lens discomfort ➤ Company registers new artificial intelligence visual field exam device with FDA ➤ Positive Phase 3 results for faricimab for DME ➤ Research begins to create a MIGS patient-reported outcomes instrument ➤ ASCRS events
Where do drops fit in the era of interventional glaucoma—a time when there are new technologies, new drug delivery systems, and several MIGS options?
Depending on what you define as a microinvasive glaucoma surgery (MIGS), you might think it first became available several decades ago with endocyclophotocoagulation (ECP), but many define the MIGS era beginning with the iStent (Glaukos), the first ab interno trabecular microbypass device approved by the FDA in 2012.
Described as a “hybrid” MIGS device, surgeons discuss the XEN Gel Stent, patient selection, the surgical technique, and more.
Pigmentary glaucoma, though a less common glaucoma subtype, is still something specialists need to learn to look for, knowing the more common patient demographics, management options, and more.
Get the latest ophthalmology news delivered to your inbox every Friday.